Get started
Author

Rin Inamoto

Observed name: R. Inamoto
ORCID: 0009-0009-5696-518X
Observed ORCID: 0009-0009-5696-518X
OpenAlex ID: A5028925216
Safety and Efficacy of Cold Snare Polypectomy Without Submucosal Injection for Large Sessile Serrated Lesions: A Prospective Study
2020 · Yoshiaki Kimoto, Eiji Sakai, et al. · Clinical Gastroenterology and Hepatology · 53
PDF
Claudin18.2 in Advanced Gastric Cancer
2023 · Rin Inamoto, Naoki Takahashi, et al. · Cancers · 40
PDF
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
2024 · Hisato Kawakami, Koki Nakanishi, et al. · Gastric Cancer · 21
PDF
Endoscopic and histological features of Helicobacter pylori ‐negative differentiated gastric adenocarcinoma arising in the antrum
2021 · Maiko Takita, Ken Ohata, et al. · JGH Open · 20
PDF
A new classification for the diagnosis of superficial non‐ampullary duodenal epithelial tumors using endocytoscopy: A prospective study
2021 · Takashi Muramoto, Ken Ohata, et al. · Journal of Gastroenterology and Hepatology · 12
Endoscopic submucosal dissection using an ultrathin endoscope for superficial pharyngeal cancer: a prospective feasibility study (with video)
2022 · Takashi Muramoto, Ken Ohata, et al. · Endoscopy International Open · 9
PDF
Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study
2025 · K. Nakanishi, N. Sugimoto, et al. · ESMO Gastrointestinal Oncology · 4
PDF
Colon cancer of Peutz-Jeghers syndrome with gallolyticus endocarditis
2019 · Kiyoshi Miyahara, Shunichi Tobe, et al. · Clinical Journal of Gastroenterology · 4
PDF
Correlation between PD-L1 CPS and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan.
2025 · Misa Onishi, Nozomu Ogura, et al. · Journal of Clinical Oncology · 2
PDF
Successful esophageal endoscopic submucosal dissection with intraoperative release of stenosis due to previous endoscopic submucosal dissection scarring
2022 · Rindo Ishii, Ken Ohata, et al. · DEN Open · 2
PDF
Association of the PD ‐ L1 CPS With the Efficacy of First‐Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer
2026 · Nozomu Ogura, Misa Ohnishi, et al. · Cancer Medicine · 1
Impact of prior immune checkpoint inhibitor on trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory analysis of the EN-DEAVOR study
2025 · Yukiya Narita, Hisato Kawakami, et al. · Japanese Journal of Clinical Oncology · 1
A retrospective observational study to evaluate the efficacy of trifluridine/tipiracil ± bevacizumab in metastatic colorectal cancer with MSI-high/deficient MMR.
2025 · Rin Inamoto, Hiroko Hasegawa, et al. · Journal of Clinical Oncology · 1
PDF
Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
2024 · Hisato Kawakami, Koki Nakanishi, et al. · Gastric Cancer · 1
Retrospective cohort study to evaluate the efficacy and safety of T-DXd in HER2-positive unresectable advanced or recurrent gastric or gastroesophageal junction cancer: EN-DEAVOR study.
2024 · Koki Nakanishi, Yasuhiro Kodera, et al. · Journal of Clinical Oncology · 1
PDF
Trifluridine/tipiracil with or without bevacizumab in microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: A retrospective observational study
2026 · Hiroko Hasegawa, Rin Inamoto, et al. · Therapeutic Advances in Medical Oncology
Clinical Impact of Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Gastric Cancer and Ascites: Findings From the EN-DEAVOR Study
2026 · Keiko Minashi, Rin Inamoto, et al. · Journal of the Korean Gastric Cancer Association
PDF
879eP Prophylactic effect of diclofenac sodium gel on hand-foot syndrome in patients with gastrointestinal cancer treated with tyrosine kinase inhibitors : A single-center prospective observational study
2025 · R. Inamoto, N. Takahashi, et al. · Annals of Oncology
421P Prognostic impact of the modified Glasgow prognostic score in advanced gastric and gastroesophageal junction cancer treated with first-line nivolumab plus chemotherapy: A multi-center retrospective study
2025 · N. Ogura, M. Onishi, et al. · Annals of Oncology
427P Safety and efficacy of nivolumab plus chemotherapy in patients with advanced gastric cancer with ascites: A multi-center retrospective study in Japan
2025 · M. Onishi, M. Furuta, et al. · Annals of Oncology
PDF
420P Impact of early tumor shrinkage as a prognostic predictor in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan
2025 · R. Inamoto, N. Takahashi, et al. · Annals of Oncology
PDF
426P The strategy of planned discontinuation of oxaliplatin for advanced gastric cancer treated with nivolumab plus chemotherapy: A multi-center retrospective study
2025 · M. Furuta, M. Onishi, et al. · Annals of Oncology
PDF
Correlation between immune-related adverse events and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center retrospective study in Japan.
2025 · Rin Inamoto, Nozomu Ogura, et al. · Journal of Clinical Oncology
PDF
396. Short-term Review: Real-word Experience of Pembrolizumab as First-line Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma
2024 · Takako Yoshii, Hiroki Hara, et al. · Diseases of the Esophagus
PDF
Can "Clear-Through® with increased volume type" have higher patient acceptance while maintaining colon cleansing?
2021 · Yoshiaki Kimoto, Yohei Minato, et al. · Progress of Digestive Endoscopy
PDF
Works count: 25
Citation count: 172
H-index: 6
I10-index: 5
Year
Topic
Type